Blood Res.  2017 Jun;52(2):77-78. 10.5045/br.2017.52.2.77.

Dapsone therapy for immune thrombocytopenic purpura: old but still unfamiliar

• Song J

• KMID: 2413320
• DOI: http://doi.org/10.5045/br.2017.52.2.77

Abstract

No abstract available.

MeSH Terms

Dapsone*
Purpura, Thrombocytopenic, Idiopathic*
Dapsone

Reference

1. Cooper N. State of the art - how I manage immune thrombocytopenia. Br J Haematol. 2017; 177:39–54.

2. Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost. 2013; 11:1946–1953.

3. Lee JY, Lee J, Jung JY, Bang S. Dapsone therapy for refractory immune thrombocytopenia patients: a case series. Blood Res. 2017; 52:95–99.

4. Moss C, Hamilton PJ. Thrombocytopenia in systemic lupus erythematosus responsive to dapsone. BMJ. 1988; 297:266.

5. Durand JM, Lefèvre P, Hovette P, Issifi S, Mongin M. Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection. Am J Med. 1991; 90:675–677.

6. Godeau B, Oksenhendler E, Bierling P. Dapsone for autoimmune thrombocytopenic purpura. Am J Hematol. 1993; 44:70–72.

7. Durand JM, Lefèvre P, Hovette P, Mongin M, Soubeyrand J. Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol. 1991; 78:459–460.

8. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults-a report on 90 patients. Eur J Haematol. 2005; 75:328–331.

9. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014; 306:103–124.

10. Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017; 17:262–275.